Berek and Hacker's Gynecologic Oncology. (Record no. 28814)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 10943nam a22004813i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC6743421 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240724115255.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2020 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781975142650 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9781975142643 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC6743421 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL6743421 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)1273976376 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RC280.G5 B474 2021 |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.99/465 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Berek, Jonathan. |
| 245 10 - TITLE STATEMENT | |
| Title | Berek and Hacker's Gynecologic Oncology. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 7th ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Philadelphia : |
| Name of producer, publisher, distributor, manufacturer | Wolters Kluwer Health, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2020. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2020. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (1727 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Cover -- Title Page -- Copyright -- Dedication -- Contributors -- Foreword to the First Edition -- Preface -- Contents -- Section I: General Principles -- Chapter 1: Cancer Genetics -- Historic Perspective -- Genetic Changes -- Sporadic -- Hereditary -- Oncogenes -- Types of Oncogenes -- Tumor Suppressor Genes (Anti-Oncogenes) -- Epigenetic Changes -- Genetic Changes in Gynecologic Malignancies -- Endometrial Cancer -- Uterine Mesenchymal Tumors -- Ovarian Cancer -- Ovarian Sex Cord Stromal Tumors -- Cervical Cancer -- Vulvar Cancer -- Gestational Trophoblastic Disease -- Chapter 2: Cancer Cell Biology -- Cell Growth and Proliferation -- Oncogenes -- Tumor Suppressor Genes -- DNA Repair -- DNA Damage Response Defects and Synthetic Lethality to Enhance Efficacy of Cancer Therapy -- Cell Death Pathways -- Autophagy -- Apoptosis -- Necrosis -- Cancer Stem Cells -- Cellular Senescence -- Cell Metabolism -- Hormone Metabolism -- Post-translational Modifications -- Cell Invasion and Metastasis -- Epithelial-to-Mesenchymal Transition -- Tumor Microenvironment -- Immune Checkpoints -- Angiogenesis -- Biomarkers -- Tumor Markers -- Chapter 3: Biologic, Targeted, and Immune Therapy -- Inhibitors of Growth Factor Receptors -- EGFR Inhibitors -- EGFR Inhibitors-Small Molecules -- EGFR Inhibitors-Monoclonal Antibodies -- Her2/Neu Inhibitors -- Her2/Neu Inhibitors-Small Molecules -- Her2/Neu Inhibitors-Monoclonal Antibodies -- PDGFR Inhibitors-Monoclonal Antibodies -- Inhibitors of Angiogenesis -- VEGFR Inhibitors-Small Molecules -- VEGFR Inhibitors-Monoclonal Antibodies -- Inhibitors of Other Intracellular Kinases -- Small Molecules -- Braf (Rapidly Activated Fibrosarcoma) Inhibitors -- MEK1-2 (MAPK/ERK Kinase) Inhibitors -- CDK 4-6 (Cyclin-Dependent Kinases 4-6) Inhibitors -- ALK (Anaplastic Lymphoma Kinase) Inhibitors. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | PI-3K (Phosphatidylinositol 3-Kinase) Inhibitors -- mTOR (Mammalian Target of Rapamycin) Inhibitors -- Inhibitors of DNA Repair -- PARP (Poly-ADP Ribose-Polymerase) Inhibitors -- Immunotherapy -- Cytokines -- Monoclonal Antibodies -- Immune Checkpoint Inhibitors -- Anti-PD-1 (Programmed Cell Death Receptor-1) Antibodies -- Anti-PD-L1 (Programmed Cell Death Receptor Ligand-1) Antibodies -- Therapeutic Cancer Vaccines -- Cell-Based Vaccines -- Glycan-Based Vaccines -- Adoptive Cell Therapy -- Chapter 4: Chemotherapy -- General Principles -- Tumor Growth and Chemotherapy -- Differential Sensitivity -- Therapeutic Index -- Brief History of Chemotherapy -- Biologic Factors Influencing Treatment -- Cell Kinetic Concepts -- Cancer Cell Growth -- Principles of Chemotherapy -- Neoadjuvant Chemotherapy -- Hyperthermic Intraperitoneal Chemotherapy -- Antibody-Drug Conjugates -- Chemotherapy in Pregnancy -- Drug Resistance -- Excretion -- Drug Interactions -- Combination Chemotherapy -- Clinical Benefit -- RECIST Criteria -- Dose Adjustment -- Carboplatin Dose Calculation -- Toxicities and Their Management -- Antineoplastic Drugs -- Alkylating Agents -- Antitumor Antibiotics and Topoisomerase Inhibitors -- Antimetabolites -- Plant Alkaloids (Mitotic Spindle Agents) -- Chapter 5: Radiation Therapy -- Radiation Biology -- Radiation Damage and Repair -- Cell Survival Curves -- Fractionation -- Dose-Rate Effect -- The Four Rs -- Treatment Strategies for Overcoming Radioresistance of Hypoxic Cells -- Linear-Energy Transfer and Relative Biologic Effectiveness -- Hyperthermia -- Interactions between Radiation and Drugs -- Radiation Therapy and the Immune System -- Therapeutic Ratio -- Effects of Radiation on Normal Tissues -- Scoring of Late Complications of Radiation Therapy. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Treatment Strategies to Exploit Differences Between Tumor and Normal Tissue in the Response to Fractionated Radiation Therapy -- Combinations of Surgery and Radiation Therapy -- Physical Principles -- Ionizing Radiations Used in Therapy -- Interactions of Radiation With Matter -- Measurement of Absorbed Dose -- Inverse Square Law -- Radiation Techniques -- External Beam Irradiation -- Brachytherapy -- Palliation -- Chapter 6: Pathology -- Cervix -- Squamous Lesions of the Cervix -- Human Papilloma Virus -- Cervicovaginal Cytology-Pap Testing -- Glandular Lesions of the Cervix -- Mesenchymal Tumors -- Vagina -- Squamous Lesions of the Vagina -- Glandular Lesions of the Vagina -- Fibroepithelial Stromal Polyp -- Sarcoma Botryoides -- Melanoma -- Postoperative Spindle Cell Nodule -- Vulva -- Squamous Cell Lesions of the Vulva -- Other Vulvar Lesions -- Mesenchymal Tumors -- Aggressive Angiomyxoma -- Melanocytic Tumors -- Uncommon Neoplasms -- Uterine Corpus -- Endometrial Neoplasms -- Endometrial Carcinoma -- Histologic Types -- Histologic Grading of Endometrioid Carcinoma -- Pathologic Staging of Endometrial Carcinoma -- Mesenchymal Neoplasms -- Uterine Tumor Resembling Ovarian Sex Cord-Stromal Tumor -- Endometrial Stromal Tumors -- Undifferentiated Uterine Sarcoma -- Other Uterine Mesenchymal Tumors -- Mixed Müllerian Neoplasms -- Adenofibroma -- Atypical Polypoid Adenomyoma -- Adenosarcoma -- Carcinosarcoma -- Ovary -- Ovarian Epithelial Tumors -- Sex Cord-Stromal Tumors -- Germ Cell Tumors -- Embryonal Carcinoma -- Miscellaneous Ovarian Tumors -- Secondary Tumors of the Ovary-Metastases -- Nonneoplastic Lesions of the Ovary -- Luteinized Ovarian Conditions -- Fallopian Tube -- Primary Tubal Carcinoma -- Adenomatoid Tumor -- Gestational Trophoblastic Disease -- Hydatidiform Mole -- Choriocarcinoma -- Placental Site Trophoblastic Tumor. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Chapter 7: Epidemiology and Biostatistics -- Descriptive Statistics -- Incidence -- Prevalence -- Cancer Survival -- Etiologic Studies -- Case-Control Study -- Cohort Studies -- Statistical Inference and Validity -- Statistical Inference -- Statistical Distributions and Tests -- Validity -- Other Criteria for Judging an Epidemiologic Study -- Cancer Risk and Prevention -- Cervical Cancer -- Endometrial Cancer -- Ovarian Cancer -- Other Gynecologic Neoplasms -- Cancer Prevention -- Secondary Prevention -- Test Definitions -- Sensitivity -- Specificity -- Predictive Value -- Screening Strategies -- Section II: Disease Sites -- Chapter 8: Preinvasive Disease -- Cervix -- Classification of Preinvasive Cervical Disease -- Understanding the Cervical Transformation Zone -- IFCPC Colposcopic Terminology of the Cervix, Vagina, and Vulva -- Systematic Approach to Colposcopy -- Indications for Colposcopy -- Human Papillomaviruses and Cervical Neoplasia -- Human Papillomavirus Vaccines -- The WHO Initiative for the Elimination of Cervical Cancer as a Public Health Problem -- Screening for Cervical Neoplasia -- Treatment of Cervical Intraepithelial Neoplasia -- Treatment Modalities -- Vagina -- Classification of Vaginal Intraepithelial Neoplasia -- Clinical Profile -- Diagnosis -- Treatment of High-Grade Vaginal Intraepithelial Neoplasia -- Vulva and Perianal Area -- Classification -- Paget Disease -- Clinical Profile of High-Grade Vulvar Intraepithelial Neoplasia (uVIN) -- Diagnosis -- Natural History of High-Grade Vulvar Intraepithelial Neoplasia -- Differentiated Vulvar Intraepithelial Neoplasia (dVIN) -- Treatment of High-Grade Vulvar Intraepithelial Neoplasia -- HPV Vaccination -- Multicentric Lower Genital Tract Neoplasia -- Chapter 9: Cervical Cancer -- Diagnosis -- Symptoms -- Signs -- Biopsy -- Colposcopy for Invasive Cancer -- Staging. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Noninvasive Diagnostic Studies -- Surgical Staging -- Patterns of Spread -- Direct Infiltration -- Lymphatic Spread -- Hematogenous Spread -- Treatment -- Microinvasive Carcinoma -- 2018 FIGO Stages IB1, IB2, and Early-Stage IIA1 Cervical Cancer -- Stage IB3 Cervical Carcinoma -- Prognostic Factors for Stages IB to IIA -- Stages IIB to IVA Disease -- Nonsquamous Histologic Types -- Adenocarcinoma -- Adenosquamous Carcinoma -- Glassy Cell Carcinoma -- Adenoma Malignum (Minimum Deviation Adenocarcinoma) -- Adenoid Cystic Carcinoma -- Adenoid Basal Carcinoma -- Clear Cell Adenocarcinoma -- Villoglandular Papillary Adenocarcinoma -- Small-Cell, including Small-Cell Neuroendocrine Carcinoma -- Large-Cell Neuroendocrine Carcinoma -- Serous Carcinoma -- Sarcoma -- Lymphoma -- Verrucous Carcinoma -- Melanoma -- Metastatic Carcinoma -- Cancer of the Cervical Stump -- Invasive Cancer Found after Simple Hysterectomy -- Coexistent Pelvic Mass -- Cervical Bleeding -- Recurrent Cervical Cancer -- Radical Hysterectomy for Recurrence -- Chemotherapy -- Chapter 10: Uterine Cancer -- Prevention of Disease and Screening of Asymptomatic Women -- Clinical Features -- Symptoms -- Signs -- Diagnosis -- Preoperative Investigations -- Staging -- Spread Patterns -- Prognostic Variables -- Age -- Histologic Type -- Histologic Grade and Myometrial Invasion -- Vascular Space Invasion -- Results of Peritoneal Cytology -- Hormone Receptor Status -- Nuclear Grade -- Tumor Size -- DNA Ploidy and Other Biologic Markers -- Body Mass Index -- Method of Treatment -- Endometrial Hyperplasia -- Diagnosis -- Treatment -- Treatment of Endometrial Cancer -- Stage I and Stage II Occult -- Clinical Stage II -- Surgical Stage IIIA -- Surgical Stage IIIB -- Surgical Stage IVA -- Surgical Stage IVB -- Special Clinical Circumstances -- Recurrent Endometrial Cancer -- Isolated Vaginal Recurrence. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Nodal Recurrence. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Generative organs, Female-Cancer. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hacker, Neville F. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Berek, Jonathan |
| Title | Berek and Hacker's Gynecologic Oncology |
| Place, publisher, and date of publication | Philadelphia : Wolters Kluwer Health,c2020 |
| International Standard Book Number | 9781975142643 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=6743421">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=6743421</a> |
| Public note | Click to View |
No items available.